Labradimil, formerly known as RMP 7, is a bradykinin B2 receptor agonist potentially for the treatment of brain cancer. RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. RMP-7 enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. RMP-7 increases carboplatin levels in brain tumors after pretreatment with dexamethasone. References: Kuo YC, Lee CL. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. Colloids Surf B Biointerfaces. 2012 Feb 1;90:75-82. doi: 10.1016/j.colsurfb.2011.09.048. Epub 2011 Oct 6. PubMed PMID: 22024400.

纯度：≥98%

CAS：159768-75-9